{
    "2021-07-23": [
        [
            {
                "time": "",
                "original_text": "小摩减持康龙化成(03759)约23.34万股，每股作价173.834港元 减持股份",
                "features": {
                    "keywords": [
                        "小摩",
                        "减持",
                        "康龙化成"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【权益变动】康龙化成(03759.HK)被摩根大通减持23.3435万股 减持股份",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "摩根大通",
                        "减持"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "13家医药生物公司获机构频繁调研",
                "features": {
                    "keywords": [
                        "医药生物",
                        "机构调研"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "【异动股】CRO板块下挫，皓元医药(688131.CN)跌9.31%",
                "features": {
                    "keywords": [
                        "CRO",
                        "板块下挫",
                        "皓元医药"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【行情】CRO概念午后持续走弱，皓元医药跌超9%，美迪西、凯莱英、康龙化成、阳光诺和跟跌",
                "features": {
                    "keywords": [
                        "CRO",
                        "走弱",
                        "皓元医药",
                        "康龙化成"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "A股午盘综述：创业板指下挫1.8%，券商领衔周期股逆势走强",
                "features": {
                    "keywords": [
                        "A股",
                        "创业板指",
                        "下挫",
                        "券商",
                        "周期股"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "券商",
                        "周期股"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【异动股】康龙化成(03759.HK)跌4.39%",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "下跌"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "13家医药生物公司获机构调研，理邦仪器、英科医疗备受关注",
                "features": {
                    "keywords": [
                        "医药生物",
                        "机构调研",
                        "理邦仪器",
                        "英科医疗"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "医药行业2021Q2持仓分析：医药仓位持续回升 核心资产继续分化",
                "features": {
                    "keywords": [
                        "医药行业",
                        "持仓分析",
                        "核心资产分化"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}